home > pmps > summer 2005 > drug counterfeiting solutions for a wide reaching problem: starting small and evolving


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


Industry Events

Managing Risk, Complexity and Compliance

10-12 June 2015, Warsaw, Poland

Clinical trial management continues to face challenges in achieving the timelines and quality standards needed to meet ever-increasing regulatory and commercial requirements. To help PCMG members prepare and overcome these challenges, its 2015 conference will focus on three topics: risk, complexity, and compliance in clinical outsourcing.
More info >>

News and Press Releases

Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments

LONDON 3 March 2015 Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the market for its treatment. Further, popular drugs such as Almita and Avastin are nearing their patent expiry in 2015 and 2017 respectively. As such, the lung cancer therapeutics market offers vast potential that drug manufacturers are vying to tap into. Approximately 130 drugs for the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are in various stages of development and are expected to hit the market by 2020.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement